These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. High intracellular content of cyclin-dependent kinase inhibitor p27(Kip1) in early- and intermediate stage B-cell chronic lymphocytic leukemia lymphocytes predicts rapid progression of the disease. Wolowiec D, Wojtowicz M, Ciszak L, Kosmaczewska A, Frydecka I, Potoczek S, Urbaniak-Kujda D, Kapelko-Slowik K, Kuliczkowski K. Eur J Haematol; 2009 Apr; 82(4):260-6. PubMed ID: 19187271 [Abstract] [Full Text] [Related]
26. A novel role of the CX3CR1/CX3CL1 system in the cross-talk between chronic lymphocytic leukemia cells and tumor microenvironment. Ferretti E, Bertolotto M, Deaglio S, Tripodo C, Ribatti D, Audrito V, Blengio F, Matis S, Zupo S, Rossi D, Ottonello L, Gaidano G, Malavasi F, Pistoia V, Corcione A. Leukemia; 2011 Aug; 25(8):1268-77. PubMed ID: 21546901 [Abstract] [Full Text] [Related]
27. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. Contri A, Brunati AM, Trentin L, Cabrelle A, Miorin M, Cesaro L, Pinna LA, Zambello R, Semenzato G, Donella-Deana A. J Clin Invest; 2005 Feb; 115(2):369-78. PubMed ID: 15650771 [Abstract] [Full Text] [Related]
30. Diminished DNA synthesis in T cells from B chronic lymphocytic leukemia after phytohemagglutinin, anti-CD3, and phorbol myristate acetate mitogenic signals. Prieto A, Garcia-Suarez J, Reyes E, Lapeña P, Hernandez M, Alvarez-Mon M. Exp Hematol; 1993 Nov; 21(12):1563-9. PubMed ID: 8405237 [Abstract] [Full Text] [Related]
33. The interplay of CD150 and CD180 receptor pathways contribute to the pathobiology of chronic lymphocytic leukemia B cells by selective inhibition of Akt and MAPK signaling. Gordiienko I, Shlapatska L, Kholodniuk V, Sklyarenko L, Gluzman DF, Clark EA, Sidorenko SP. PLoS One; 2017 Nov; 12(10):e0185940. PubMed ID: 28982149 [Abstract] [Full Text] [Related]